To compare the effects of megestrol acetate and placebo on body weight, anorexia, cachexia, calorie intake, and nutritional parameters of patients with a confirmed diagnosis of AIDS. To determine whether megestrol acetate relative to placebo improves the perception of well-being among AIDS patients with cachexia. To evaluate megestrol acetate's effect on immune function via skin test reactivity, T4/T8 ratio, and total lymphocytes.

Condition	Treatment or Intervention	Phase
Anorexia Cachexia HIV Infections	Drug: Megestrol acetate	Phase III

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria

Patient must have:

• Confirmed diagnosis of AIDS (CDC definition).
• Documented weight loss or anorexia.
• Life expectancy = or > 20 weeks.
• The perception that the weight loss is a detriment to their well-being.
• Ability to provide informed consent, read and write English.

Exclusion Criteria

Co-existing Condition: Patients with the following conditions are excluded:

• Dementia or evidence of mental incompetence which would preclude compliance with the protocol.
• Severe diarrhea defined as 5 or more watery stools per day for at least 7 days.
• Active uncontrolled systemic infections at the start of treatment.
• Patients may not be entered for at least 2 weeks after acute infection.
• Clinical or radiologic evidence of ascites or pleural effusions.

Patients with the following are excluded:

• Obstruction to food intake or impaired digestive/absorptive functions.
• Contraindications to megestrol acetate (poorly controlled hypertension or heart failure or deep vein thrombosis).
• Inability to consent or be available for close follow-up.
• Active systemic infections at the start of treatment.
• Clinical or radiologic evidence of ascites or pleural effusions.
• Patients who have been hospitalized or have suffered an exacerbation of their illness associated with weight loss within the past 2 weeks are excluded.
• Menstruating female patients are excluded.

Prior Medication: Excluded:

• Corticosteroids.
• Anabolic steroids.
• Marijuana.
• Megestrol acetate.
• Patients who have been started on zidovudine (AZT) within 8 weeks. (Patients may have been previously treated with AZT and failed or may currently be receiving AZT for at least 8 weeks.)

Patients may not be started on any therapy designed to treat the underlying HIV infection or which may have a major impact on appetite and/or weight gain.

• Patients who have been started on zidovudine (AZT) within 8 weeks. (Patients may have been previously treated with AZT and failed or may currently be receiving AZT for at least 8 weeks.)

History of substance abuse and questionable current and future abstinence.

California
      San Francisco AIDS Clinic / San Francisco Gen Hosp, San Francisco,  California,  941102859,  United States
      Summitt Med Ctr / San Francisco Gen Hosp, Oakland,  California,  94609,  United States
      Palo Alto Veterans Adm Med Ctr / Stanford Univ, Palo Alto,  California,  94304,  United States
      San Francisco Veterans Administration Med Ctr, San Francisco,  California,  94121,  United States
      UCD Med Ctr, Sacramento,  California,  95817,  United States
      Dr Mark Goldstein, Los Angeles,  California,  90048,  United States
      Eisenhower Med Ctr, Rancho Mirage,  California,  92270,  United States
Colorado
      Denver Public Health Dept, Denver,  Colorado,  80204,  United States
Florida
      Univ of South Florida, Tampa,  Florida,  33612,  United States
      Miami Veterans Administration Med Ctr, Miami,  Florida,  33125,  United States
Illinois
      Northwestern Univ Med School, Chicago,  Illinois,  60611,  United States
New York
      SUNY / Health Sciences Ctr at Syracuse, Syracuse,  New York,  13210,  United States
      Mem Sloan - Kettering Cancer Ctr, New York,  New York,  10021,  United States
Washington
      Northwest Family Ctr at the Harbor View Med Ctr, Seattle,  Washington,  98104,  United States

Study ID Numbers:  025B; MEG8809
Record last reviewed:  August 2004
Last Updated:  October 13, 2004
Record first received:  November 2, 1999
ClinicalTrials.gov Identifier:  NCT00002067
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08